Role of endothelin in renal function and dysfunction

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 4, 1996, Pages 345-348

  Brooks, David P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

endothelin; endothelin receptors; nephrotoxicity; renovascular function

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; CONTRAST MEDIUM; CP 170687; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN; ENDOTHELIN; ENDOTHELIN RECEPTOR; RES 701 1; S6C; UNCLASSIFIED DRUG;

CONFERENCE PAPER; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; NEPHROTOXICITY;

EID: 0029954742     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb02835.x     Document Type: Conference Paper

References (68)

1. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
2. Bruzzi I, Benigni A. Endothelin is a key modulator of progressive renal injury: Experimental data and novel therapeutic strategies. Clin. Exp. Pharmacol. Physiol. 1996; 23: 349-53.
3. Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of ET-1 in healthy human volunteers. Am. J. Physiol. 1994; 35: F411-18.
4. Kon V, Yoshioka T, Fogo A, Ichikawa I. Glomerular actions of ET in vivo. J. Clin. Invest. 1989; 83: 1762-7.
5. Edwards RM, Trizna W, Ohlstein EH. Renal microvascular effects of ET. Am. J. Physiol. 1990; 259: F217-21.
6. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to ET in the rat kidney. J. Clin. Invest. 1989; 83: 336-42.
7. King AJ, Brenner BM, Anderson S. Endothelin: A potent renal and systemic vasoconstrictor peptide. Am. J. Physiol. 1989; 256: F1051-8.
8. Brooks DP, DePalma PD, Pullen M, Nambi P. Characterization of canine renal ET receptor subtypes and their function. J. Pharmacol. Exp. Ther. 1994; 268: 1091-7.
9. Brooks DP, DePalma PD, Gellai M et al. Non-peptide ET receptor antagonists III. Effect of SB 209670 and BQ123 on acute renal failure in anesthetized dogs. J. Pharmacol. Exp. Ther. 1994; 271: 769-75.
10. Stier CT Jr, Quilley CP, McGiff JC. Endothelin-3 effects on renal function and prostanoid release in the rat isolated kidney. J. Pharmacol. Exp. Ther. 1992; 262: 252-62.
11. Cristol J-P, Warner TD, Thiemermann C, Vane JR. Mediation via different receptors of the vasoconstrictor effects of ETs and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br. J. Pharmacol. 1993; 108: 776-9.
12. Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR. Comparative studies with the ET receptor antagonists BQ123 and PD142893 indicate at least three ET receptors. J. Cardiovasc. Pharmacol. 1993; 22 (Suppl. 8): S117-20.
13. A receptor activation. Am. J. Physiol. 1993; 264: R222-6.
14. A receptor antagonist in the rat. J. Clin. Invest. 1994; 93: 900-6.
15. B receptor-mediated vasoconstrictor effects of ET-1 in the rat kidney. Br. J. Pharmacol 1994; 111: 515-20.
16. B receptors increases glomerular cGMP via an L-arginine-dependent pathway. Am. J. Physiol. 1992; 263: F1020-5.
17. Harris PJ, Zhuo J, Mendelsohn FAO, Skinner SL. Haemodynamic and renal tubular effects of low doses of ET in anaesthetized rats. J. Physiol. 1991; 433: 25-39.
18. Takabatake T, Ise T, Ohta K, Kobayashi K-I. Effects of ET on renal hemodynamics and tubuloglomerular feedback. Am. J. Physiol. 1992; 263: F103-8.
19. Uzuner K, Banks RO. Endothelin-induced natriuresis and diuresis are pressure-dependent events in the rat. Am. J. Physiol. 1993; 265: R90-6.
20. Perico N, Cornejo RP, Benigni A, Malanchini B, Ladny JR, Remuzzi G. Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediated by lipoxygenase products. J. Am. Soc. Nephrol. 1991; 2: 57-69.
21. Terada Y, Tomita K, Nonoguchi H, Marumo F. Different localization of two types of ET receptor mRNA in microdissected rat nephron segments using reverse transcription and polymerase chain reaction assay. J. Clin. Invest. 1992; 90: 107-12.
22. B receptor subtypes in the dog kidney. J. Cardiovasc. Pharmacol. 1995; 26 (Suppl. 3): S322-5.
23. Kon V, Badr KF. Biological actions and pathophysiologic significance of ET in the kidney. Kidney Int. 1991; 40: 1-12.
24. Kohan DE. Endothelins in the kidney: Physiology and pathophysiology. Am. J. Kidney Dis. 1993; 22: 493-510.
25. Marsen TA, Schramek H, Dunn MJ. Renal actions of ET: Linking cellular signaling pathways to kidney disease. Kidney Int. 1994; 45: 336-44.
26. Moore K, Wendon J, Frazer M, Karani J, Williams R, Badr K. Plasma ET immunoreactivity in liver disease and the hepatorenal syndrome. N. Engl. J. Med. 1992; 327: 1774-8.
27. Morise Z, Ueda M, Aiura K, Endo M, Kitajima M. Pathophysiologic role of ET-1 in renal function in rats with endotoxin shock. Surgery 1994; 115: 199-204.
28. Ohta K, Hirata Y, Shichiri M, Ichioka M, Kubota T, Marumo F. Cisplatin-induced urinary ET excretion. JAMA 1991; 265: 1391-2.
29. Heyman SN, Clark BA, Kaiser N et al. In vivo and in vitro studies on the effect of amphotericin B on ET release. J. Antimicrob. Chemother. 1992; 29: 69-77.
30. Kelleher JP, Shah V, Godley ML et al. Urinary ET (ET1) in complete ureteric obstruction in the miniature pig. Urol. Res. 1992; 20: 63-5.
31. Tomita K, Ujiie K, Nakanishi T et al. Plasma ET levels in patients with acute renal failure. Eur. J. Med. 1989; 32: 1127.
32. Shibouta Y, Suzuki N, Shino A et al. Pathophysiological role of ET in acute renal failure. Life Sci. 1990; 46: 1611-18.
33. Firth JD, Ratcliffe PJ. Organ distribution of the three rat ET messenger RNAs and the effects of ischemia on renal gene expression. J. Clin. Invest. 1992; 90: 1023-31.
34. Clozel M, Löffler BM, Gloor H. Relative preservation of the responsiveness to ET-1 during reperfusion following renal ischemia in the rat. J. Cardiovasc. Pharmacol. 1991; 17 (Suppl. 7): S313-15.
35. Nambi P, Pullen M, Jugus M, Gellai M. Rat kidney ET receptors in ischemia-induced acute renal failure. J. Pharmacol. Exp. Ther. 1993; 264: 345-8.
36. Wilkes BM, Pearl AR, Mento PF, Maita ME, Macica CM, Girardi EP. Glomerular ET receptors during initiation and main-tenance of ischemic acute renal failure in rats. Am. J. Physiol. 1991; 260: F110-18.
37. Roubert P, Gillard-Roubert V, Pourmarin L et al. Endothelin receptor subtypes A and B are up-regulated in an experimental model of acute renal failure. Mol. Pharmacol. 1993; 45: 182-8.
38. López-Farré A, Gómez-Garre D, Bernabeu F, López-Novoa J. A role for ET in the maintenance of post-ischaemic renal failure in the rat. J. Physiol. 1991; 444: 513-22.
39. Mino N, Kobayashi M, Nakajima A et al. Protective effect of a selective ET receptor antagonist, BQ123, in ischemic acute renal failure in rats, Eur. J. Pharmacol. 1992; 221: 77-83.
40. Chan L, Chittinandana A, Shapiro JI, Shanley PF, Schrier RW. Effect of an ET-receptor antagonist on ischemic acute renal failure. Am. J. Physiol. 1994; 266: F135-8.
41. Gellai M, Jugus M, Fletcher TA et al. Nonpeptide endothelin receptor antagonists V: Prevention and reversal of acute renal failure in the rat by SB 209670. J. Pharmacol. Exp. Ther. 1995; 275: 200-6.
42. Clozel M, Breu V, Burri K et al. Pathophysiological role of ET revealed by the first orally active ET receptor antagonist. Nature 1993; 365: 759-61.
43. Stingo AJ, Clavell AL, Aarhus LL, Burnett JC Jr. Biological role for the ET-A receptor in aortic cross-clamping. Hypertension 1993; 22: 62-6.
44. Nir A, Clavell AL, Heublein D, Aarhus LL, Burnett JC Jr. Acute hypoxia and endogenous renal ET. J. Am. Soc. Nephrol. 1994; 4: 1920-4.
45. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of ET by cultured human endothelial cells. J. Clin. Invest. 1991; 88: 310-14.
46. Nakahama H. Stimulatory effect of cyclosporine A on ET secretion by a cultured renal epithelial cell line, LLC-PK1 cells. Eur. J. Pharmacol. 1990; 180: 191-2.
47. Moutabarrik A, Ishibashi M, Fukunaga M et al. FK506 mechanism of nephrotoxicity: Stimulatory effect on ET secretion by cultured kidney cells. Transplant. Proc. 1991; 23: 3133-6.
48. Nambi P, Pullen M, Contino LC, Brooks DP. Upregulation of renal ET receptors in rats with cyclosporine A-induced nephrotoxicity. Eur. J. Pharmacol. 1990; 187: 113-16.
49. Awazu M, Sugiura M, Inagami T, Ichikawa I, Kon V. Cyclosporine promotes glomerular ET binding in vivo, J. Am. Soc. Nephrol. 1991; 1: 1253-8.
50. B receptors in response to cyclosporine in mesangial cells. Am. J. Pathol. 1994; 144: 473-9.
51. Benigni A, Perico N, Ladny JR, Imberti O, Bellizzi L, Remuzzi G. Increased urinary excretion of ET-1 and its precursor, big-ET-1, in rats chronically treated with cyclosporine. Transplantation 1991; 52: 175-7.
52. Brooks DP, Ohlstein EH, Contino LC et al. Effect of nifedipine on cyclosporine A-induced nephrotoxicity, urinary ET excretion and renal ET receptor number. Eur. J. Pharmacol. 1991; 194: 115-17.
53. Edwards BS, Hunt SA, Fowler MB, Valentine HA, Anderson LM, Lerman A. Effect of cyclosporine on plasma ET levels in humans after cardiac transplantation. Am. J. Cardiol. 1991; 67: 782-4.
54. Grieff M, Loertscher R, Shohaib SA, Stewart DJ. Cyclosporine-induced elevation in circulating endothelin-1 in patients with solid-organ transplants. Transplantation 1993; 56: 880-4.
55. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. Role of ET in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990; 37: 1487-91.
56. Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J. Am. Soc. Nephrol 1990; 1: 76-83.
57. Fogo A, Hellings SE, Inagami T, Kon V. Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicity. Kidney Int. 1992; 42: 770-4.
58. Bloom ITM, Bentley FR, Garrison RN. Acute cyclosporine-induced renal vasoconstriction is mediated by ET-1. Surgery 1993; 114: 480-8.
59. A and TxA2 receptor antagonists on cyclosporin A renal vasoconstriction. Am. J. Physiol. 1994; 267: F443-9.
60. Brooks DP, Contino LC. Prevention of cyclosporine A-induced renal vasoconstriction by the endothelin receptor antagonist, SB 209670. Eur. J. Pharmacol. 1995; 294: 571-6.
61. Lanese DM, Conger JD. Effects of ET receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles. J. Clin. Invest. 1993; 91: 2144-9.
62. Cantley LG, Spokes K, Clark B, McMahon EG, Carter J, Epstein FH. Role of ET and prostaglandins in radiocontrast-induced renal artery constriction. Kidney Int. 1993; 44: 1217-23.
63. Kohan DE, Padilla E. Osmolar regulation of ET-1 production by rat inner medullary collecting duct. J. Clin. Invest. 1993; 91: 1235-40.
64. Schramek H, Gstraunthaier G, Willinger CC, Pfaller W. Hyperosmolality regulates ET release by Madin-Darby canine kidney cells. J. Am. Soc. Nephrol. 1993; 4: 206-13.
65. Yang T, Terada Y, Nonoguchi H, Ujiie K, Tomita K, Marumo F. Effect of hyperosmolality on production and mRNA expression of ET-1 in inner medullary collecting duct. Am. J. Physiol. 1993; 264: F684-9.
66. Margulies KB, Hildebrand FL, Heublein DM, Burnett JC Jr. Radiocontrast increases plasma and urinary ET. J. Am. Soc. Nephrol. 1991; 2: 1041-5.
67. Heyman SN, Clark BA, Kaiser N et al. Radiocontrast agents induce ET release in vivo and in vitro. J. Am. Soc. Nephrol. 1992; 3: 58-65.
68. Brooks DP, DePalma PD. Blockade of radiocontrast-induced renal vasoconstriction by the ET receptor antagonist, SB 209670. Nephron 1996 (in press).